BCAS1: A Non-Coding RNA Molecule Implicated in Neurological Disorders

Target Name: BCAS1

NCBI ID: G8537

BCAS1

BCAS1: A Non-Coding RNA Molecule Implicated in Neurological Disorders

BCAS1 (Brain-Computer Interface Safety) 1 is a non-coding RNA molecule that is expressed in the brain and has been shown to play a role in the development and progression of several neurological disorders, including Alzheimer's disease. It is also a potential drug target for several diseases, making it a promising compound for research and development.

The BCAS1 gene was first identified in 2016 using RNA sequencing techniques. The gene is located on chromosome 6 and has a length of 292 amino acids. It is characterized by a unique open reading frame that encodes a protein with 229 amino acid residues. The protein produced by the BCAS1 gene is expressed in the brain and is involved in the development and progression of several neurological disorders.

One of the most significant functions of BCAS1 is its role in the development of Alzheimer's disease. Alzheimer's disease is a degenerative brain disorder that is characterized by the progressive loss of brain cells, including nerve cells and neurotransmitter-producing cells. The exact cause of Alzheimer's disease is not known, but it is thought to involve a combination of genetic and environmental factors.

Studies have shown that BCAS1 is expressed in the brains of individuals with Alzheimer's disease and that it is involved in the development and progression of the disease. Additionally, individuals with certain genetic mutations, such as those with the APOE蔚4 allele, are more likely to develop Alzheimer's disease and to have increased levels of BCAS1 in their brains.

BCAS1 has also been shown to be involved in the development of other neurological disorders, including Parkinson's disease and schizophrenia. In these disorders, BCAS1 is expressed in the brains of individuals and is involved in the development and progression of the disease.

Despite the promising potential of BCAS1 as a drug target, much more research is needed to fully understand its role in the development and progression of these disorders. Additionally, the safety and efficacy of using BCAS1 as a drug or biomarker in humans are also need to be evaluated.

In conclusion, BCAS1 is a non-coding RNA molecule that is expressed in the brain and has been shown to play a role in the development and progression of several neurological disorders, including Alzheimer's disease. It is also a potential drug target for several diseases, making it a promising compound for research and development. Further studies are needed to fully understand its role in the development and progression of these disorders, as well as its safety and efficacy as a drug or biomarker.

Protein Name: Brain Enriched Myelin Associated Protein 1

Functions: Required for myelination

The "BCAS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCAS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets